Project Name: Coventry and Warwickshire Integrated Care System Secondary prevention ASCVD pharmacist led service
Project Summary:
The main objective of the CWP is to improve the quality of care for patients treated for Atherosclerotic Cardiovascular Disease (ASCVD) within Coventry and Warwickshire Integrated Care System (ICS) specifically acute coronary syndrome (ACS), with a particular focus on long term risk factor management and the transition of care between secondary and primary care who are at high risk of cardiovascular events or experienced a cardiac event and who are not achieving lipid levels as specified in national and/or local guidance, in response to the needs of the CW Partner. This will be achieved by implementing and adopting the Accelerated Access Collaborative (AAC) guidelines across the ICS alongside the standardization of the cardiac rehab services across the integrated Care System (ICS) and through the development of a cardiac rehab services at South Warwickshire University foundation trust (SWFT) and George Eliot Hospital NHS Trust (GEH) that will mirror the established cardiac rehab service at UHCW.
The secondary objective is to reduce the current backlog of patients waiting to be seen (2 months) by the UHCW lipid service by implementing a local secondary care led secondary prevention clinic, focusing on supporting the discharge and onward management of secondary prevention patients, including first dose medicine optimization, and subsequent transfer to primary care setting.
This will be achieved by the funding for an additional Clinical Pharmacist Band 8A to develop and support a lipid Optimisation service offered by the current lipid service and cardiac rehab departments across the ICS.
Planned Milestones:
| 1 | Project Kick off meeting |
| 2 | CW Partner: Collection of baseline data, in line with the above Project Outcome Measures & Data Collection table |
| 3 | CW Partner: Confirmation of clinical and operational pathway, policy and protocol creation, and readiness to begin the clinical activity (CW Partner shall ensure that the clinical staff covered by the Novartis Financial Contribution are in place, trained and ready to begin clinical activity). |
| 4 | CW Partner: Confirmation of recruitment of Clinical Pharmacist Band 8A and completion of onboarding |
| 5 | CW Partner: Collection & submission of 3 months:- clinical activity data & educational activities CW Partner & Novartis: Project Review meeting to discuss project progress. |
| 6 | Setting up the clinics at SWFT and George Eliot |
| 7 | CW Partner: Collection & submission of 6 months clinical activity data & educational activities CW Partner & Novartis: Project Review meeting to discuss project progress. |
| 8 | CW Partner: Development of business case to continue the service offered by this project |
| 9 | CW Partner: Collection & submission of 9 months clinical activity data & educational activities CW Partner & Novartis: Project Review meeting to discuss project progress. |
| 10 | CW Partner: Collection & submission of 12 months clinical activity data & educational activities CW Partner & Novartis: Project Review meeting to discuss project progress. |
| 11 | CW Partner: Development of business case with 12 months data to continue the service offered by this project |
| 12 | CW Partner: Analysis of CWP data, submission of Final Project Report, Submission of Outcomes Summary |
Expected Benefits:
ANTICIPATED BENEFITS FOR PATIENTS
- Improved access to lipid management care leading to optimal diagnosis and management of ASCVD treatments.
- Enhanced experience around ASCVD with ongoing management of the condition.
- Improved access to appropriate medication for suitable patients to preserve health and prevent long-term events.
- Easier access to lipid management care closer to home in the Primary Care setting coordinated by secondary care.
The additional capacity will provide additional time and support from PCN HCP with their lipid management, focusing on patients who may have previously not attended GP appointment or been lost to follow-up.
ANTICIPATED BENEFITS FOR THE ORGANISATION(S)
- Increased proportion of ASCVD patients reviewed.
- Increased proportion of ASCVD patients receiving expert and timely review closer to home
- Reduction in ASCVD referral rates to secondary care
- Increased proportion of patients receiving guideline-directed pharmacotherapy
- Insight into benefits of primary care pharmacist led lipid management clinics in primary care
- Support aligned to NHS Long Term Plan, CVDPREVENT, and Network Contract DES
ANTICIPATED BENEFITS FOR NOVARTIS
- Insight on the appropriate use of ASCVD licensed medicines in line with NICE guidelines, including Novartis’s medicine
- Enhanced reputation, and supporting Novartis’ vision that no patient should have to wait for an extraordinary life, by supporting high quality Collaborative Working with healthcare organisations which addresses the problem of health inequalities
- Ethical, professional, and transparent relationship between Novartis and the Healthcare Organisation
Start Date & Duration: October 2023 for 13 months
UK2310041939